{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:05:30Z","timestamp":1779858330371,"version":"3.53.1"},"reference-count":136,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.xphs.2025.103952","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:14:39Z","timestamp":1755011679000},"page":"103952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pulmonary drug delivery of clofazimine: A route of administration and pharmacokinetics guided repositioning strategy against drug resistant tuberculosis informed by use for other disease indications"],"prefix":"10.1016","volume":"114","author":[{"given":"Kolimi Prashanth","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurdeep","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7404-4917","authenticated-orcid":false,"given":"Pallab","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.xphs.2025.103952_bib0001","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1469-0691.2011.03716.x","article-title":"Clofazimine in the treatment of multidrug-resistant tuberculosis","volume":"18","author":"Xu","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.xphs.2025.103952_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofx147","article-title":"Clofazimine in nontuberculous mycobacterial infections: a growing niche","volume":"4","author":"McGuffin","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.xphs.2025.103952_bib0003","first-page":"67","article-title":"Clofazimine inhalation suspension demonstrates promising toxicokinetics in canines for treating pulmonary nontuberculous mycobacteria infection","author":"Kunkel","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2025.103952_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005373","article-title":"A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis","author":"Love","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"10.1016\/j.xphs.2025.103952_bib0005","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bcp.2013.12.007","article-title":"Anti-leprosy drug clofazimine inhibits growth of triple-negative breast cancer cells via inhibition of canonical Wnt signaling","volume":"87","author":"Koval","year":"2014","journal-title":"Biochem Pharmacol"},{"issue":"7859","key":"10.1016\/j.xphs.2025.103952_bib0006","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-021-03431-4","article-title":"Clofazimine broadly inhibits coronaviruses including SARS-CoV-2","volume":"593","author":"Yuan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xphs.2025.103952_bib0007","article-title":"Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters","author":"Yuan","year":"2020","journal-title":"Res Sq"},{"issue":"November 2024","key":"10.1016\/j.xphs.2025.103952_bib0008","article-title":"Clofazimine enhances anti-glioma effect of immunotherapy","volume":"145","author":"Kosianova","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.xphs.2025.103952_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.136921","article-title":"Clofazimine inhibits small-cell lung cancer progression by modulating the kynurenine\/aryl hydrocarbon receptor axis","volume":"282","author":"Sharma","year":"2024","journal-title":"Int J Biol Macromol"},{"issue":"5","key":"10.1016\/j.xphs.2025.103952_bib0010","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.ccell.2024.03.001","article-title":"Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy","volume":"42","author":"Xue","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xphs.2025.103952_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115539","article-title":"Clofazimine: a journey of a drug","volume":"167","author":"Xu","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"25","key":"10.1016\/j.xphs.2025.103952_bib0012","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang\u2019wa","year":"2022","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2025.103952_bib0013","article-title":"Impacts of clofazimine on the treatment outcomes of drug-resistant tuberculosis","volume":"25","author":"Wang","year":"2023","journal-title":"Microbes Infect"},{"issue":"8","key":"10.1016\/j.xphs.2025.103952_bib0014","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1128\/AAC.00395-15","article-title":"Mode of action of clofazimine and combination therapy with benzothiazinones against mycobacterium tuberculosis","volume":"59","author":"Lechartier","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"January","key":"10.1016\/j.xphs.2025.103952_bib0015","article-title":"Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against mycobacterium tuberculosis","volume":"10","author":"Islam","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.xphs.2025.103952_bib0016","doi-asserted-by":"crossref","DOI":"10.1021\/acsinfecdis.4c00767","article-title":"Pharmacokinetic and pharmacodynamics of clofazimine nano-in-microparticles: enhanced brain delivery and CNS tuberculosis amelioration via intranasal administration","author":"Jadhav","year":"2025","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.xphs.2025.103952_bib0017","doi-asserted-by":"crossref","unstructured":"Mansj\u00f6, M.; Espinosa-gongora, C.; Samanci, I.; Groenheit, R.; Werngren, J. The EUCAST reference protocol. 2025, 69 (2).","DOI":"10.1128\/aac.00946-24"},{"issue":"9 September","key":"10.1016\/j.xphs.2025.103952_bib0018","first-page":"1","article-title":"Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant mycobacterium tuberculosis in Ethiopia","volume":"17","author":"Getahun","year":"2022","journal-title":"PLoS One"},{"issue":"December","key":"10.1016\/j.xphs.2025.103952_bib0019","doi-asserted-by":"crossref","first-page":"7587","DOI":"10.2147\/IDR.S440711","article-title":"Bedaquiline, delamanid, linezolid, clofazimine, and capreomycin MIC distributions for drug resistance mycobacterium tuberculosis in Shanghai, China","volume":"16","author":"Guo","year":"2023","journal-title":"Infect Drug Resist"},{"issue":"Suppl 3","key":"10.1016\/j.xphs.2025.103952_bib0020","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/infdis\/jiu610","article-title":"Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia","volume":"211","author":"Gumbo","year":"2015","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.xphs.2025.103952_bib0021","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00749-10","article-title":"An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future","volume":"55","author":"Pasipanodya","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2025.103952_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-00529-6","article-title":"Pharmacokinetic-pharmacodynamic modelling of intracellular mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration","volume":"7","author":"Aljayyoussi","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.xphs.2025.103952_bib0023","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/cid\/ciac511","article-title":"Pharmacokinetic-pharmacodynamic determinants of clinical outcomes for rifampin-resistant tuberculosis: a multisite prospective cohort study","volume":"76","author":"Heysell","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.xphs.2025.103952_bib0024","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaoto.2021.2404","article-title":"A novel case of clofazimine-induced purple nasal mucosal discoloration","volume":"147","author":"Fischer","year":"2021","journal-title":"JAMA Otolaryngol Neck Surg"},{"issue":"4","key":"10.1016\/j.xphs.2025.103952_bib0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/tmi.13977","article-title":"Clofazimine-induced cutaneous hyperpigmentation as a source of stigma in the treatment of leprosy: a cross-sectional study","volume":"29","author":"Nogueira","year":"2024","journal-title":"Trop Med Int Heal"},{"issue":"3","key":"10.1016\/j.xphs.2025.103952_bib0026","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4269\/ajtmh.22-0637","article-title":"Case report: borderline lepromatous leprosy therapy complicated by type 1 leprosy reaction and adverse reactions with dapsone and clofazimine","volume":"110","author":"Matono","year":"2024","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"10.1016\/j.xphs.2025.103952_bib0027","article-title":"Clofazimine pulmonary crystal deposition syndrome: a case of pseudo haemoptysis","volume":"17","author":"Rechal","year":"2024","journal-title":"BMJ Case Reports CP"},{"issue":"S 01","key":"10.1016\/j.xphs.2025.103952_bib0028","doi-asserted-by":"crossref","first-page":"E578","DOI":"10.1055\/a-2344-8244","article-title":"Clofazimine enteropathy: a case of pigmentation of the whole small intestine caused by clofazimine","volume":"56","author":"Zhang","year":"2024","journal-title":"Endoscopy"},{"key":"10.1016\/j.xphs.2025.103952_bib0029","first-page":"4498","article-title":"Quantifying the reversibility of clofazimine-induced pigmentation in a patient with Mycobacterium abscessus; pulmonary disease","author":"Ito","year":"2024","journal-title":"Intern Med"},{"key":"10.1016\/j.xphs.2025.103952_bib0030","doi-asserted-by":"crossref","DOI":"10.11604\/pamj.2022.42.14.34956","article-title":"Clofazimine induced pigmentation in leprosy patches","volume":"42","author":"Chavhan","year":"2022","journal-title":"Pan Afr Med J"},{"key":"10.1016\/j.xphs.2025.103952_bib0031","series-title":"Article Images in Clinical Medicine Clofazimine-Induced Skin Pigmentation","author":"Karnan","year":"2024"},{"issue":"3","key":"10.1016\/j.xphs.2025.103952_bib0032","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12664-020-01128-6","article-title":"Clofazimine-related duodenal pigmentation","volume":"40","author":"Bhangale","year":"2021","journal-title":"Indian J Gastroenterol"},{"issue":"3","key":"10.1016\/j.xphs.2025.103952_bib0033","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jid.2017.09.031","article-title":"The physicochemical basis of clofazimine-induced skin pigmentation","volume":"138","author":"Murashov","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"December 2023","key":"10.1016\/j.xphs.2025.103952_bib0034","first-page":"211","article-title":"In vivo deposition of poorly soluble drugs","author":"Lou","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"issue":"March","key":"10.1016\/j.xphs.2025.103952_bib0035","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jconrel.2022.05.029","article-title":"Molecular design of a pathogen activated, self-assembling mechanopharmaceutical device","volume":"347","author":"Willmer","year":"2022","journal-title":"J Control Release"},{"issue":"5","key":"10.1016\/j.xphs.2025.103952_bib0036","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jmii.2024.08.002","article-title":"Clofazimine and QT prolongation in the treatment of rifampicin-resistant tuberculosis: findings of ADSM in Taiwan","volume":"57","author":"Lin","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"issue":"11","key":"10.1016\/j.xphs.2025.103952_bib0037","doi-asserted-by":"crossref","first-page":"486","DOI":"10.5588\/ijtldopen.24.0490","article-title":"Updated treatment guidelines for drug-resistant tb: how safe are clofazimine-based regimens?","volume":"1","author":"Pontali","year":"2024","journal-title":"IJTLD OPEN"},{"key":"10.1016\/j.xphs.2025.103952_bib0038","series-title":"Clofazimine Is a Safe and Effective Alternative For Rifampicin in Mycobacterium Avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial","author":"Zweijpfenning","year":"2023"},{"key":"10.1016\/j.xphs.2025.103952_bib0039","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz456","article-title":"Clinical outcomes of clofazimine use for rapidly growing mycobacterial infections","author":"Carey","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.xphs.2025.103952_bib0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1183\/13993003.02445-2016","article-title":"Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil","volume":"49","author":"Dalcolmo","year":"2017","journal-title":"Eur Respir J"},{"issue":"April","key":"10.1016\/j.xphs.2025.103952_bib0041","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.biopha.2018.06.023","article-title":"Clofazimine: a useful antibiotic for drug-resistant tuberculosis","volume":"105","author":"Mirnejad","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.xphs.2025.103952_bib0042","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jcf.2019.05.013","article-title":"Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections","volume":"18","author":"Banaschewski","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.xphs.2025.103952_bib0043","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jac\/dkae041","article-title":"Why do we use 100 mg of clofazimine in TB and NTM treatment?","volume":"79","author":"van Ingen","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.xphs.2025.103952_bib0044","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1093\/jac\/dkaa310","article-title":"Clofazimine pharmacokinetics in patients with TB: dosing implications","volume":"75","author":"Abdelwahab","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.xphs.2025.103952_bib0045","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1128\/AAC.00260-15","article-title":"Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis","volume":"59","author":"Swanson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"May","key":"10.1016\/j.xphs.2025.103952_bib0046","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jconrel.2022.05.029","article-title":"Molecular design of a pathogen activated, self-assembling mechanopharmaceutical device","volume":"347","author":"Willmer","year":"2022","journal-title":"J Control Release"},{"issue":"6","key":"10.1016\/j.xphs.2025.103952_bib0047","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tube.2004.04.001","article-title":"Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid","volume":"84","author":"Nix","year":"2004","journal-title":"Tuberculosis"},{"key":"10.1016\/j.xphs.2025.103952_bib0048","article-title":"Pharmacokinetics and safety of clofazimine in children with rifampicin-resistant tuberculosis","author":"Jid","year":"2025","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.xphs.2025.103952_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/aac.00794-23","article-title":"Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis","volume":"68","author":"Ali","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.xphs.2025.103952_bib0050","first-page":"66","article-title":"Pharmacokinetics and adverse effects of clofazimine in the treatment of pulmonary non-tuberculous mycobacterial infection","author":"Watanabe","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.xphs.2025.103952_bib0051","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1093\/jac\/dkae309","article-title":"A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease","volume":"79","author":"Stemkens","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.xphs.2025.103952_bib0052","series-title":"Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine","author":"Village","year":"2022"},{"key":"10.1016\/j.xphs.2025.103952_bib0053","series-title":"MannKind \u2019 s Inhaled Clofazimine Will Advance to an Adaptive Phase 2 \/3 Study For Potential Treatment of Rare Lung Disease","author":"Village","year":"2023"},{"issue":"9","key":"10.1016\/j.xphs.2025.103952_bib0054","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00186-22","article-title":"Respirable clofazimine particles produced by air jet milling technique are efficacious in treatment of BALB\/c mice with chronic mycobacterium tuberculosis infection","volume":"66","author":"Brunaugh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.xphs.2025.103952_bib0055","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1016\/j.apsb.2024.08.027","article-title":"Solubilization techniques used for poorly water-soluble drugs","volume":"14","author":"Xie","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"10.1016\/j.xphs.2025.103952_bib0056","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1021\/acs.molpharmaceut.3c00172","article-title":"Clofazimine PKa determination by potentiometry and spectrophotometry: reverse cosolvent dependence as an indicator of the presence of dimers in aqueous solutions","volume":"20","author":"Verbi\u0107","year":"2023","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2025.103952_bib0057","first-page":"36","article-title":"An Expandable mechanopharmaceutical device (2): drug induced granulomas maximize the cargo sequestering capacity of macrophages in the liver","author":"Rzeczycki","year":"2019","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2025.103952_bib0058","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010017","article-title":"An adaptive biosystems engineering approach towards modeling the soluble-to-insoluble phase transition of clofazimine","volume":"14","author":"Willmer","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.xphs.2025.103952_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-42180-3","article-title":"Acoustic tweezing cytometry for mechanical phenotyping of macrophages and mechanopharmaceutical cytotripsy","volume":"9","author":"Hong","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.xphs.2025.103952_bib0060","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1128\/AAC.01731-12","article-title":"Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration response","volume":"57","author":"Baik","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.xphs.2025.103952_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics15092350","article-title":"Distinguishing the concentration- vs. bioaccumulation-dependent immunological and metabolic effects of clofazimine","volume":"15","author":"Willmer","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.xphs.2025.103952_bib0062","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1128\/AAC.01897-12","article-title":"Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice","volume":"57","author":"Verma","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2025.103952_bib0063","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01560-21","article-title":"Pharmacokinetics and pharmacodynamics of clofazimine for treatment of cryptosporidiosis","volume":"66","author":"Zhang","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"May","key":"10.1016\/j.xphs.2025.103952_bib0064","article-title":"Development of low-cost, weight-adjustable clofazimine mini-tablets for treatment of tuberculosis in pediatrics","volume":"187","author":"Warnken","year":"2023","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2025.103952_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/ph15020120","article-title":"Solidification of self-emulsifying drug delivery systems as a novel approach to the management of uncomplicated malaria","volume":"15","author":"Seo","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"December 2021","key":"10.1016\/j.xphs.2025.103952_bib0066","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jconrel.2021.12.003","article-title":"Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport","volume":"341","author":"Elz","year":"2022","journal-title":"J Control Release"},{"issue":"April","key":"10.1016\/j.xphs.2025.103952_bib0067","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejpb.2023.04.009","article-title":"Improvement and characterization of oral absorption behavior of clofazimine by SNEDDS: quantitative evaluation of extensive lymphatic transport","volume":"187","author":"Yamanouchi","year":"2023","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"10.1016\/j.xphs.2025.103952_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103782","article-title":"Highly Increasing solubility of clofazimine, an extremely water-insoluble basic drug, in lipid-based SEDDS using digestion products of long-chain lipids","volume":"114","author":"Kandagatla","year":"2025","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2025.103952_bib0069","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16060768","article-title":"In vitro predictive model for intestinal lymphatic uptake: exploration of additional enhancers and inhibitors","volume":"16","author":"Yousef","year":"2024","journal-title":"Pharmaceutics"},{"issue":"October 2020","key":"10.1016\/j.xphs.2025.103952_bib0070","article-title":"Intestinal delivery in a long-chain fatty acid formulation enables lymphatic transport and systemic exposure of orlistat","volume":"596","author":"Lee","year":"2021","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2025.103952_bib0071","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1021\/acs.molpharmaceut.9b00276","article-title":"Solid-state behavior and solubilization of flash nanoprecipitated clofazimine particles during the dispersion and digestion of milk-based formulations","volume":"16","author":"Salim","year":"2019","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2025.103952_bib0072","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1021\/acs.cgd.6b01411","article-title":"Investigation into the solid and solution properties of known and novel polymorphs of the antimicrobial molecule clofazimine","volume":"16","author":"Bannigan","year":"2016","journal-title":"Cryst Growth Des"},{"issue":"10","key":"10.1016\/j.xphs.2025.103952_bib0073","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1021\/acs.molpharmaceut.7b00521","article-title":"Design and solidification of fast-releasing clofazimine nanoparticles for treatment of cryptosporidiosis","volume":"14","author":"Zhang","year":"2017","journal-title":"Mol Pharm"},{"issue":"November 2017","key":"10.1016\/j.xphs.2025.103952_bib0074","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejps.2017.11.004","article-title":"Development of PLGA nanoparticles loaded with clofazimine for oral delivery: assessment of formulation variables and intestinal permeability","volume":"112","author":"Chaves","year":"2018","journal-title":"Eur J Pharm Sci"},{"issue":"00","key":"10.1016\/j.xphs.2025.103952_bib0075","first-page":"1","article-title":"Design, development, and characterisation of clofazimine-loaded mannosylated nanostructured lipid carriers : 3 -box-behnken design approach","volume":"00","author":"Patil","year":"2020","journal-title":"Mater Technol"},{"issue":"3","key":"10.1016\/j.xphs.2025.103952_bib0076","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/03639045.2021.1892743","article-title":"Nanostructured lipid carrier-mediated lung targeted drug delivery system to enhance the safety and bioavailability of clofazimine","volume":"47","author":"Patil","year":"2021","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.xphs.2025.103952_bib0077","doi-asserted-by":"crossref","unstructured":"Gui, Y.; Mccann, E.C.; Yao, X.; Li, Y.; Jones, K.J.; Yu, L. Amorphous drug \u2212 polymer salt with high stability under tropical conditions and fast dissolution: the case of clofazimine and poly(acrylic acid). 2021. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c01180.","DOI":"10.1021\/acs.molpharmaceut.0c01180"},{"key":"10.1016\/j.xphs.2025.103952_bib0078","doi-asserted-by":"crossref","unstructured":"Chen, W.; Cheng, C.; Lee, B.; et al. A facile strategy enabling both high loading and high release amounts of the water-insoluble drug clofazimine using mesoporous silica nanoparticles. 2018. https:\/\/doi.org\/10.1021\/acsami.8b09069.","DOI":"10.1021\/acsami.8b09069"},{"issue":"17","key":"10.1016\/j.xphs.2025.103952_bib0079","doi-asserted-by":"crossref","first-page":"11899","DOI":"10.1039\/C7CP08328A","article-title":"Fluorescence imaging of antibiotic clofazimine encapsulated within mesoporous silica particle carriers: relevance to drug delivery and the effect on its release kinetics","volume":"20","author":"Angiolini","year":"2018","journal-title":"Phys Chem Chem Phys"},{"issue":"17","key":"10.1016\/j.xphs.2025.103952_bib0080","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1039\/C7TB00198C","article-title":"Mesoporous silica particles as a lipophilic drug vehicle investigated by fluorescence lifetime imaging","volume":"5","author":"Valetti","year":"2017","journal-title":"J Mater Chem B"},{"issue":"8","key":"10.1016\/j.xphs.2025.103952_bib0081","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2217\/nnm-2016-0364","article-title":"Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant mycobacterium tuberculosis infections","volume":"12","author":"Valetti","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.xphs.2025.103952_bib0082","first-page":"1214","article-title":"A new salt of clofazimine to improve leprosy treatment","author":"Sousa","year":"2020","journal-title":"J Mol Struct"},{"issue":"12","key":"10.1016\/j.xphs.2025.103952_bib0083","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1021\/cg301463z","article-title":"Clofazimine mesylate: a high solubility stable salt","volume":"12","author":"Bolla","year":"2012","journal-title":"Cryst Growth Des"},{"issue":"January","key":"10.1016\/j.xphs.2025.103952_bib0084","article-title":"Pulmonary inhalation for disease treatment: basic research and clinical translations","volume":"25","author":"Wang","year":"2024","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.xphs.2025.103952_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2021.112612","article-title":"Cationic inhalable particles for enhanced drug delivery to M. tuberculosis infected macrophages","volume":"133","author":"Sharma","year":"2022","journal-title":"Biomater Adv"},{"issue":"1","key":"10.1016\/j.xphs.2025.103952_bib0086","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s11095-008-9626-z","article-title":"Shape induced inhibition of phagocytosis of polymer particles","volume":"26","author":"Champion","year":"2009","journal-title":"Pharm Res"},{"issue":"April","key":"10.1016\/j.xphs.2025.103952_bib0087","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2024.05.026","article-title":"Phospholipids of inhaled liposomes determine the in vivo fate and therapeutic effects of salvianolic acid b on idiopathic pulmonary fibrosis","volume":"371","author":"Peng","year":"2024","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.xphs.2025.103952_bib0088","first-page":"100","article-title":"\u4e73\u9f20\u5fc3\u808c\u63d0\u53d6 HHS Public Access","volume":"176","author":"Micha","year":"2017","journal-title":"Physiol Behav"},{"issue":"12","key":"10.1016\/j.xphs.2025.103952_bib0089","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12121196","article-title":"Novel approaches for the treatment of pulmonary tuberculosis","volume":"12","author":"Tan","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2025.103952_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep23528","article-title":"Repositioning clofazimine as a macrophage-targeting photoacoustic contrast agent","volume":"6","author":"Keswani","year":"2016","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.xphs.2025.103952_bib0091","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1021\/acs.molpharmaceut.7b00690","article-title":"Excipient-free pulmonary delivery and macrophage targeting of clofazimine via air jet micronization","volume":"14","author":"Brunaugh","year":"2017","journal-title":"Mol Pharm"},{"issue":"August","key":"10.1016\/j.xphs.2025.103952_bib0092","article-title":"Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation","volume":"154","author":"Jadhav","year":"2023","journal-title":"Biomater Adv"},{"issue":"March","key":"10.1016\/j.xphs.2025.103952_bib0093","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jconrel.2024.03.013","article-title":"Inhalable porous particles as dual micro-nano carriers demonstrating efficient lung drug delivery for treatment of tuberculosis","volume":"369","author":"Campos Pacheco","year":"2024","journal-title":"J Control Release"},{"issue":"December 2023","key":"10.1016\/j.xphs.2025.103952_bib0094","article-title":"Preparation and in vitro characterization of clofazimine-loaded albumin nanocomposite microparticles for inhalation therapy","volume":"93","author":"Gao","year":"2024","journal-title":"J Drug Deliv Sci Technol"},{"issue":"5","key":"10.1016\/j.xphs.2025.103952_bib0095","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40265-019-01095-z","article-title":"Amikacin liposome inhalation suspension: a review in mycobacterium avium complex lung disease","volume":"79","author":"Shirley","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.xphs.2025.103952_bib0096","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofad682","article-title":"Treatment outcomes of clofazimine-containing regimens in severe mycobacterium avium complex pulmonary disease","volume":"11","author":"Lee","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"January","key":"10.1016\/j.xphs.2025.103952_bib0097","article-title":"Recent advances in aerosolised drug delivery","volume":"112","author":"Chandel","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"January","key":"10.1016\/j.xphs.2025.103952_bib0098","article-title":"The future of dry powder inhaled therapy: promising or discouraging for systemic disorders?","volume":"614","author":"Ye","year":"2022","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2025.103952_bib0099","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ijpharm.2018.07.050","article-title":"Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs","volume":"549","author":"Kukut Hatipoglu","year":"2018","journal-title":"Int J Pharm"},{"issue":"September","key":"10.1016\/j.xphs.2025.103952_bib0100","article-title":"Engineering of pulmonary surfactant corona on inhaled nanoparticles to operate in the lung system","volume":"52","author":"Falahati","year":"2023","journal-title":"Nano Today"},{"key":"10.1016\/j.xphs.2025.103952_bib0101","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114309","article-title":"Pulmonary delivery nanomedicines towards circumventing physiological barriers: strategies and characterization approaches","volume":"185","author":"Wang","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2025.103952_bib0102","doi-asserted-by":"crossref","DOI":"10.1021\/acs.langmuir.4c00909","article-title":"A review on investigating the interactions between nanoparticles and the pulmonary surfactant monolayer with coarse-grained molecular dynamics method","author":"Tang","year":"2024","journal-title":"Langmuir"},{"issue":"12","key":"10.1016\/j.xphs.2025.103952_bib0103","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1021\/nn4054683","article-title":"Physicochemical properties of nanoparticles regulate translocation across pulmonary surfactant monolayer and formation of lipoprotein corona","volume":"7","author":"Hu","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.xphs.2025.103952_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114561","article-title":"Engineering the right formulation for enhanced drug delivery","volume":"191","author":"Ke","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"10.1016\/j.xphs.2025.103952_bib0105","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/17425247.2018.1502267","article-title":"Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies","volume":"15","author":"Osman","year":"2018","journal-title":"Expert Opin Drug Deliv"},{"issue":"June 2023","key":"10.1016\/j.xphs.2025.103952_bib0106","article-title":"\u201cNano-in-micro\u201d structured dry powder inhalers for pulmonary delivery: advances and challenges","volume":"96","author":"Cao","year":"2024","journal-title":"J Drug Deliv Sci Technol"},{"issue":"July","key":"10.1016\/j.xphs.2025.103952_bib0107","article-title":"Impact of simulated lung fluid components on the solubility of inhaled drugs and predicted in vivo performance","volume":"606","author":"Radivojev","year":"2021","journal-title":"Int J Pharm"},{"issue":"April","key":"10.1016\/j.xphs.2025.103952_bib0108","article-title":"Development of inhaled formulation of modified clofazimine as an alternative to treatment of tuberculosis: clofazimine inhaled formulation for tuberculosis","volume":"58","author":"de Castro","year":"2020","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.xphs.2025.103952_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114468","article-title":"Solid state of inhalable high dose powders","volume":"189","author":"Adhikari","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2025.103952_bib0110","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.powtec.2014.04.066","article-title":"A study of jet-milling and spray-drying process for the physicochemical and aerodynamic dispersion properties of amiloride HCl","volume":"262","author":"Djoki\u0107","year":"2014","journal-title":"Powder Technol"},{"issue":"February","key":"10.1016\/j.xphs.2025.103952_bib0111","article-title":"Excipient-free inhalable combination shell-core microparticles with clofazimine as shell for extended pulmonary retention of isoniazid in core","volume":"672","author":"Reddy","year":"2025","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2025.103952_bib0112","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2003.08.010","article-title":"A simple pharmacokinetic method to evaluate the pulmonary dose in clinical practice - analysis of inhaled sodium cromoglycate","volume":"98","author":"Lindstr\u00f6m","year":"2004","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.xphs.2025.103952_bib0113","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11095-006-9174-3","article-title":"Particle engineering for pulmonary drug delivery","volume":"24","author":"Chow","year":"2007","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2025.103952_bib0114","series-title":"Current Trends in Inhaled Pharmaceuticals: Challenges and Opportunities in Respiratory Infections Treatment","author":"Shah","year":"2025"},{"issue":"March","key":"10.1016\/j.xphs.2025.103952_bib0115","first-page":"1","article-title":"Formulation of dry powders for inhalation comprising high doses of a poorly soluble hydrophobic drug","volume":"2","author":"Tarara","year":"2022","journal-title":"Front Drug Deliv"},{"issue":"4","key":"10.1016\/j.xphs.2025.103952_bib0116","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry-powder formulation of tobramycin using pulmosphere\u2122 technology","volume":"24","author":"Geller","year":"2011","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"7","key":"10.1016\/j.xphs.2025.103952_bib0117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics11070316","article-title":"Biological obstacles for identifying in vitro-in vivo correlations of orally inhaled formulations","volume":"11","author":"Fr\u00f6hlich","year":"2019","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.xphs.2025.103952_bib0118","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.xphs.2021.09.042","article-title":"In-vitro in-vivo correlation (IVIVC) of inhaled products using twin stage impinger","volume":"111","author":"Al ayoub","year":"2022","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.103952_bib0119","first-page":"151","article-title":"In vitro to ex vivo\/in vivo correlation (IVIVC) of dissolution kinetics from inhaled particulate solutes using air\/blood barrier models: relation between in vitro design, lung physiology and kinetic output of models","volume":"2021","author":"Gerde","year":"2020","journal-title":"J Aerosol Sci"},{"issue":"1","key":"10.1016\/j.xphs.2025.103952_bib0120","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1021\/acs.molpharmaceut.3c00685","article-title":"IBCS: 3. A biopharmaceutics classification system for orally inhaled drug products","volume":"21","author":"Hastedt","year":"2024","journal-title":"Mol Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2025.103952_bib0121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-019-1479-8","article-title":"Advancements in dissolution testing of oral and non-oral formulations","volume":"20","author":"Klein","year":"2019","journal-title":"AAPS PharmSciTech"},{"issue":"January","key":"10.1016\/j.xphs.2025.103952_bib0122","article-title":"Drug solubility in biorelevant media in the context of an inhalation-based biopharmaceutics classification system (IBCS)","volume":"197","author":"Floroiu","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"10.1016\/j.xphs.2025.103952_bib0123","doi-asserted-by":"crossref","first-page":"239","DOI":"10.26650\/IstanbulJPharm.2023.1005069","article-title":"In vitro dissolution testing methods for inhaled drugs","volume":"53","author":"Falade","year":"2023","journal-title":"\u0130stanbul J Pharm"},{"issue":"July","key":"10.1016\/j.xphs.2025.103952_bib0124","article-title":"Validation of a cell integrated next-generation impactor to assess in vitro drug transport of physiologically relevant aerosolised particles","volume":"624","author":"Wong","year":"2022","journal-title":"Int J Pharm"},{"issue":"May","key":"10.1016\/j.xphs.2025.103952_bib0125","first-page":"1","article-title":"Macrophage: a cell with many faces and functions in tuberculosis","volume":"13","author":"Ahmad","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2025.103952_bib0126","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-024-01124-3","article-title":"How macrophage heterogeneity affects tuberculosis disease and therapy","author":"Russell","year":"2025","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2025.103952_bib0127","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jgar.2014.12.001","article-title":"Effects of clofazimine on planktonic and biofilm growth of mycobacterium tuberculosis and mycobacterium smegmatis","volume":"3","author":"Mothiba","year":"2015","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.xphs.2025.103952_bib0128","unstructured":"Sarathy, J.P. Crossm Caseum : a Niche for Mycobacterium Tuberculosis Drug-Tolerant."},{"key":"10.1016\/j.xphs.2025.103952_bib0129","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jgar.2022.03.008","article-title":"Assessment of the efficacy of clofazimine alone and in combination with primary agents against mycobacterium tuberculosis in vitro","volume":"29","author":"Mashele","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.xphs.2025.103952_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-025-56934-3","article-title":"Exploring the principles behind antibiotics with limited resistance","volume":"16","author":"Maharramov","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.xphs.2025.103952_bib0131","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1100488","article-title":"Clofazimine for the treatment of tuberculosis","volume":"14","author":"Stadler","year":"2023","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2025.103952_bib0132","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1073\/pnas.1416951112","article-title":"Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis","volume":"112","author":"Tyagi","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.xphs.2025.103952_bib0133","first-page":"68","article-title":"Clofazimine as a substitute for rifampicin improves efficacy of mycobacterium avium pulmonary disease treatment in the hollow-fiber model","author":"Salillas","year":"2024","journal-title":"Am Soc Microbiol"},{"issue":"January","key":"10.1016\/j.xphs.2025.103952_bib0134","first-page":"1","article-title":"A clofazimine-containing regimen confers improved treatment outcomes in macrophages and in a murine model of chronic progressive pulmonary infection caused by the mycobacterium avium complex","volume":"11","author":"Lee","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.xphs.2025.103952_bib0135","doi-asserted-by":"crossref","unstructured":"Rongala, D.S.; Patil, S.M.; Kunda, N.K. Design of Experiment (DoE) approach for developing inhalable PLGA microparticles loaded with clofazimine for tuberculosis treatment. 2024.","DOI":"10.3390\/ph17060754"},{"key":"10.1016\/j.xphs.2025.103952_bib0136","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102058","article-title":"Clofazimine for treatment of multidrug-resistant non-tuberculous mycobacteria","volume":"70","author":"Pfaeffle","year":"2021","journal-title":"Pulm Pharmacol Ther"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235492500406X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235492500406X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:46:12Z","timestamp":1779857172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235492500406X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":136,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S002235492500406X"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103952","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary drug delivery of clofazimine: A route of administration and pharmacokinetics guided repositioning strategy against drug resistant tuberculosis informed by use for other disease indications","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103952"}}